For more information, please click on a name.

Michael G. Hanna, Jr., Vaccinogen Medical Advisor

With 23 years as a board-certified medical oncologist/hematologist and possessing a Master's degree in nutritional biochemistry, Dr. Boyd is a specialist in cancer treatment and recovery and is a pioneer in the field of integrative cancer care with a targeted focus on nutritional support for cancer patients.

Currently, Dr. Boyd is an attending physician at Greenwich Hospital – Yale Medical Center and is an assistant clinical professor at the Yale University School of Medicine.  Most recently, he was recruited to develop and direct the Nutrition and Integrative Medicine Curricula at Yale University School of Medicine, which he directed through 2012.

In 2010, Dr. Boyd was appointed Director of Cancer Nutrition for the Yale Health System and is developing a Center for Cancer Nutrition Education in affiliation with the Yale Smilow Cancer Survivorship Program. Dr. Boyd is also the founding president of The Integrative Cancer Care Research Foundation and a board member of Environment and Human Health, Inc., a nonprofit organization made up of physicians and public health professionals dedicated to the purpose of protecting public health from environmental harms.

Dr. Boyd is the author or co-author of 14 peer-reviewed papers and in 2005 published a book titled, The Cancer Recovery Plan

Dr. Boyd received an M.S. in nutritional biochemistry from the Institute of Human Nutrition, Columbia University, and an M.D. from Cornell University Medical College.

 

Herbert C. Hoover, Vaccinogen Medical AdvisorHerbert C. Hoover, M.D., our Medical Advisor. Dr. Hoover serves as a Consulting Medical Advisor for Vaccinogen and has been the one clinician involved in all of the clinical trials of OncoVAX®. Dr. Hoover initiated the original pilot trial of active specific immunotherapy in patients with colon cancer at Johns Hopkins Hospital in 1981. He served in a medical advisory role with Organon Teknika/Biotechnology Research, PerImmune and Intracel.

Dr. Hoover has had numerous honors and awards throughout his career including the Charles B. Thornton Advanced Technology Achievement Award (for the development of tumor-specific human monoclonal antibodies) as well as the Best Doctors in America recognition. He shares multiple patents for the development of monoclonal antibodies and active-specific immunotherapy and has published nearly 100 scientific articles.

Dr. Hoover received his M.D. from the University of Kansas School of Medicine in 1970. His surgical residency was served at the Massachusetts General Hospital and Harvard Medical School from 1970 to 1977 with a Chief Residency in 1978. He was a Clinical Associate in the Surgery Branch of the NCI, NIH in Bethesda from 1972 to 1974.

John S. Macdonald, Vaccinogen Medical AdvisorJohn S. Macdonald, M.D., professor of medicine, New York Medical College. Previously, Dr. Macdonald has served on the medical staffs at Georgetown University Medical School, University of Kentucky, Temple University New York Medical College and Saint Vincent's Hospital’s Comprehensive Cancer Center where he was chief of medical oncology.

Dr. Macdonald graduated from Harvard University medical school and is board certified in internal medicine and medical oncology as well as a specialist in gastrointestinal cancer and cancer immunotherapy. Dr. Macdonald is the recipient of the distinguished American Cancer Society Junior Faculty Fellowship as well as having received numerous awards and distinctions including being named in the Best Doctors in America listing and the Good Housekeeping "Best 300 Doctors in America."

Jan Vermorken, Vaccinogen Medical AdvisorJan Vermorken, M.D., Ph.D., Dr. Vermorken served on the medical staff of oncology, at the University Hospital Vrije Universiteit in Amsterdam, The Netherlands, and is Emeritus Professor of Oncology at the University of Antwerp and past head of the Department of Medical Oncology at the Antwerp University Hospital in Edegem, Belgium, where he still works as a consultant.  Dr. Vermorken was principal investigator of the OncoVAX® 8701 phase IIIa clinical trial.  Dr. Vermorken’s main field of interest is in gynecological oncology, and head and neck oncology.  In addition, he coordinated large clinical trials in breast and colon cancer, including the OncoVAX®’s Phase III trial (8701).  His main research areas concern early clinical and pharmacological studies with new drugs, studies on the interaction of chemotherapy and radiation therapy, HPV in various malignancies and immunological approaches.

Dr. Vermorken is a member of the European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group (GCG) and the EORTC Head and Neck Cancer Group (HNCG).  He chaired the EORTC-GCG from 1983 to 1989 and the EORTC-HNCG from 2006 to 2009.  He is still an active member with both groups. 

He is an officer for ESMO, was a member of the ESMO executive committee during the time that he chaired the ESMO National Representative Committee (1991 – 1996) and the ESMO Education Committee (1996 – 2002) and is a prominent member of the ESMO faculty.  He is also a member of the International Gynecological Cancer Society (IGCS), was founding chair of the Gynecological Cancer Intergroup (GCIG) and was Chairman of the Belgian Association of Cancer Research (BACR) from 2003 to 2011, now still being part of its board.

Dr. Vermorken is a member of six editorial boards of international journals, reviewer of 13 cancer journals and author or co-author of more than 500 publications in international journals.  Since January 2009, Dr. Vermorken has been Editor-in-Chief of Annals of Oncology. On March 1, 2013 he received the title of Commander in the Order of Leopold for his contributions to oncology.